Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease Inhibition

通过蛋白酶抑制克服新出现的烟曲霉唑抗性

基本信息

  • 批准号:
    10320260
  • 负责人:
  • 金额:
    $ 44.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-02-01 至 2024-01-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY. Infections caused by the filamentous fungus Aspergillus fumigatus and related species are associated with significant morbidity and mortality despite contemporary antifungal drug therapies. Many factors contribute to poor treatment outcomes including the physiological state of the fungus at the site of infection and the global emergence of triazole drug resistant strains. One major regulatory mechanism used by the fungus to progress disease and resist triazole drug activity is proteolytic activation of the transcriptional regulator, SrbA. Activation of SrbA in vivo is absolutely required for fungal virulence and intrinsic triazole drug resistance, as null mutants of SrbA regulatory factors such as the fungal specific activating serine protease RbdB and E3 ubiquitin ligases (DSCs) are avirulent in animal models of invasive aspergillosis (IA) and have significant increases in triazole susceptibility. The objective of this proposal in response to RFA-AI-17-036 is to identify small molecules that inhibit SrbA activation and develop them into advanced therapeutic candidates with broad-spectrum activity against triazole resistant filamentous fungi. Potent inhibitors of the SrbA- dependent signaling pathway will be developed for clinical use as an adjunctive therapy in combination with a triazole antifungal agent that is used to treat IA. The adjunctive therapy is expected to provide several advantages over triazole monotherapy, including growth inhibition in hypoxic conditions and increased antifungal activity of the triazole drug in both drug susceptible and drug resistant infections. As the SrbA pathway is conserved among most human fungal pathogens, some of which are inherently azole resistant, we anticipate broad spectrum clinical utility beyond infections caused by A. fumigatus. Our approach leverages the availability of well characterized protease and ligase inhibitor chemical libraries, both known druggable targets in many disease settings, with the expertise of Microbiotix Inc. and the Cramer Laboratory at Dartmouth. The R21 phase of this application will utilize high-throughput cell based screens of defined targeted small molecule libraries to identify and confirm SrbA regulatory protease and/or ligase inhibitors and validate their antifungal activity, pathway specificity, and mammalian toxicity of early hits and leads. In the R33 phase, validated hits will be chemically optimized, validated, defined pharmacologically, determine mechanism of action, and finally proceed to in vivo pharmacologic and toxicology profiling and antifungal efficacy in established murine models of invasive aspergillosis.
项目总结。由丝状真菌烟曲霉菌及相关物种引起的感染 尽管有现代的抗真菌药物治疗,但仍与显著的发病率和死亡率有关。许多 导致治疗效果不佳的因素包括真菌在感染部位的生理状态 感染和全球出现的三氮唑耐药菌株。使用的一种主要监管机制 真菌对疾病的进展和对三氮唑类药物的抗药性是蛋白水解酶的转录激活 监管者,sba。SrbA在体内的激活是真菌毒力和内在三氮唑药物所必需的 抗性,作为真菌特异性激活丝氨酸蛋白酶等sbA调节因子的零突变 RbdB和E3泛素连接酶(DSCs)在侵袭性曲霉病(IA)动物模型中是无毒的 三氮唑类药物敏感性显著增加。本提案针对RFA-AI-17-036的目标是 识别抑制srbA激活的小分子并将其发展为先进的候选治疗方案 对三唑耐药丝状真菌具有广谱活性。有效的srbA抑制剂- 依赖的信号通路将被开发为临床上使用的辅助疗法,与 三氮唑类抗真菌药,用于治疗IA。这种辅助疗法有望提供几种 与三氮唑单一疗法相比的优势,包括在低氧条件下抑制生长和增加 三唑类药物在药物敏感和耐药感染中的抗真菌活性。作为塞族共和军 途径在大多数人类真菌病原体中是保守的,其中一些是天生的对唑类抗药性,我们 预期除烟曲霉菌引起的感染外,还具有广泛的临床应用价值。我们的方法利用 具有良好特性的蛋白酶和连接酶抑制剂化学文库的可用性,这两个化学文库都是已知的药物靶标 在许多疾病环境中,利用MicroBiotix Inc.和达特茅斯的Cramer实验室的专业知识。这个 该应用的R21阶段将利用基于高通量细胞的已定义靶向小分子的筛选 鉴定和确认srbA调节酶和/或连接酶抑制剂并验证其抗真菌作用的文库 早期HITs和Lead的活性、途径特异性和哺乳动物毒性。在R33阶段,验证的命中率 将进行化学优化、验证、药理学定义、确定作用机制,并最终 在已建立的小鼠模型中进行体内药理和毒理学分析及抗真菌效果 侵袭性曲霉病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Andrew Cramer其他文献

Robert Andrew Cramer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Andrew Cramer', 18)}}的其他基金

Environmental Oxygen Transitions and Aspergillosis Disease Progression
环境氧转变和曲霉病进展
  • 批准号:
    10615129
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
抗真菌免疫和真菌程序性细胞死亡机制
  • 批准号:
    10538624
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Environmental Oxygen Transitions and Aspergillosis Disease Progression
环境氧转变和曲霉病进展
  • 批准号:
    10404535
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
抗真菌免疫和真菌程序性细胞死亡机制
  • 批准号:
    10320401
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease Inhibition
通过蛋白酶抑制克服新出现的烟曲霉唑抗性
  • 批准号:
    10547781
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
抗真菌免疫和真菌程序性细胞死亡机制
  • 批准号:
    10079460
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Environmental Oxygen Transitions and Aspergillosis Disease Progression
环境氧转变和曲霉病进展
  • 批准号:
    10161719
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Overcoming Emerging Aspergillus fumigatus Azole Resistance Via Protease Inhibition
通过蛋白酶抑制克服新出现的烟曲霉唑抗性
  • 批准号:
    10334562
  • 财政年份:
    2019
  • 资助金额:
    $ 44.46万
  • 项目类别:
Evolution of Aspergillus fumigatus virulence
烟曲霉毒力的演变
  • 批准号:
    10753216
  • 财政年份:
    2017
  • 资助金额:
    $ 44.46万
  • 项目类别:
Evolution of Aspergillus fumigatus virulence
烟曲霉毒力的演变
  • 批准号:
    10238878
  • 财政年份:
    2017
  • 资助金额:
    $ 44.46万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 44.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了